Ethics & Informed Consent: Retrospective Case-Control Study (Norway)

1. Ethical Principles & Legislative Framework

In research involving human participants, securing ethical clearance is a critical first step. For a Retrospective Case-Control Study being conducted in Norway, study designs must align with the primary regulatory legislation: Norwegian Health Research Act (Helseforskningsloven) 2008. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.

Administrative review and formal approval are managed by a local or regional Regional Committees for Medical and Health Research Ethics (REK). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.

2. Study Design Elements & Reporting Integrity

For a Retrospective Case-Control Study, the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.

Study Classification: Minimal Risk (Exempt or Expedited)

This design parses legacy medical archives. PIs can seek an ethical waiver of consent by documenting secure data masking pipelines and verifying minimal research risk.

To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: STROBE guidelines.

3. Informed Consent & Information Sheet Guidelines

A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:

• Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
• Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
• Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under EU GDPR & Norwegian Personal Data Act.
• Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
• Ethics Board Contact Information: Provide the contact details of the reviewing Regional Committees for Medical and Health Research Ethics (REK) so participants can reach out if they have questions or concerns.

Research Ethics, Clinical Trials & Institutional Governance

The data capture guidelines match the Declaration of Helsinki ethical principles to protect individual identifiers from disclosure. To safeguard participant confidence and avoid past clinical mistakes like the Tuskegee syphilis study ethics failures, data access is strictly gated. The consenting procedure must follow the ethical principles of informed consent, ensuring participants can opt out anytime. All registry staff must complete human subjects research training and comply with standard continuing review irb reviews. Submitting a verified data sharing agreement is necessary to secure final research ethics approval from the Regional Committees for Medical and Health Research Ethics (REK). All records and signed consent sheets must reside on secure local servers in Norway to protect patient privacy and comply with national guidelines.

4. Regulatory Checklist Table

To streamline your ethical review submission, use the structured alignment checklist below:

6. Frequently Asked Questions